$MDT
Medtronic plc Stock $mdt

$mdt Overview Financials Valuation SEC Filings Company Website

2015 Q2 Form 10-K Financial Statement

#000161310315000028 Filed on June 23, 2015

Income Statement

Concept	2015 Q2	2014 Q2	2014 Q1
Revenue	$7.304B	$4.566B	$4.163B
YoY Change	59.96%	2.38%	3.38%
Cost Of Revenue	$2.934B	$1.171B	$1.050B
YoY Change	150.56%	3.26%	5.11%
Gross Profit	$4.370B	$3.395B	$3.113B
YoY Change	28.72%	2.07%	2.81%
Gross Profit Margin	59.83%	74.35%	74.78%
Selling, General & Admin	$2.404B	$1.539B	$1.454B
YoY Change	56.21%	4.34%	3.78%
% of Gross Profit	55.01%	45.33%	46.71%
Research & Development	$528.0M	$385.0M	$360.0M
YoY Change	37.14%	-5.87%	-4.26%
% of Gross Profit	12.08%	11.34%	11.56%
Depreciation & Amortization	$677.0M	$215.0M	$214.0M
YoY Change	214.88%	2.87%	0.0%
% of Gross Profit	15.49%	6.33%	6.87%
Operating Expenses	$3.372B	$2.054B	$1.948B
YoY Change	64.17%	6.37%	3.51%
Operating Profit	$998.0M	$1.341B	$1.165B
YoY Change	-25.58%	-3.87%	1.66%
Interest Expense	-$194.0M	-$25.00M	-$25.00M
YoY Change	676.0%	-66.22%	-45.65%
% of Operating Profit	-19.44%	-1.86%	-2.15%
Other Income/Expense, Net
YoY Change
Pretax Income	$187.0M	$481.0M	$955.0M
YoY Change	-61.12%	-58.32%	-17.32%
Income Tax	$188.0M	$33.00M	$193.0M
% Of Pretax Income	100.53%	6.86%	20.21%
Net Earnings	-$1.000M	$448.0M	$762.0M
YoY Change	-100.22%	-53.77%	-22.87%
Net Earnings / Revenue	-0.01%	9.81%	18.3%
Basic Earnings Per Share	$0.00	$0.45	$0.76
Diluted Earnings Per Share	$0.00	$0.44	$0.75
COMMON SHARES
Basic Shares Outstanding	1.416B shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q2	2014 Q2	2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$19.48B	$14.24B	$13.67B
YoY Change	36.79%	27.95%	454.67%
Cash & Equivalents	$4.843B	$1.403B	$1.304B
Short-Term Investments	$14.64B	$12.84B	$12.36B
Other Short-Term Assets	$2.789B	$1.433B	$1.318B
YoY Change	94.63%	11.69%	3.29%
Inventory	$3.463B	$1.725B	$1.782B
Prepaid Expenses
Receivables	$5.112B	$3.811B	$3.619B
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$30.84B	$21.21B	$20.39B
YoY Change	45.42%	18.81%	122.53%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.699B	$2.392B	$2.408B
YoY Change	96.45%	-3.94%	-3.76%
Goodwill	$40.53B	$10.59B
YoY Change	282.61%	2.56%
Intangibles	$28.10B	$2.286B
YoY Change	1129.27%
Long-Term Investments
YoY Change
Other Assets	$1.737B	$1.162B	$1.472B
YoY Change	49.48%	-25.32%	69.98%
Total Long-Term Assets	$75.84B	$16.73B	$16.85B
YoY Change	353.24%	-1.85%	-34.68%
TOTAL ASSETS
Total Short-Term Assets	$30.84B	$21.21B	$20.39B
Total Long-Term Assets	$75.84B	$16.73B	$16.85B
Total Assets	$106.7B	$37.94B	$37.23B
YoY Change	181.17%	8.72%	6.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.610B	$742.0M	$567.0M
YoY Change	116.98%	8.96%	-0.35%
Accrued Expenses	$4.033B	$2.935B	$2.124B
YoY Change	37.41%	30.16%	2.71%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.419B	$1.613B	$2.618B
YoY Change	49.97%	77.25%	-36.21%
Total Short-Term Liabilities	$9.173B	$5.559B	$5.632B
YoY Change	65.01%	40.73%	-19.06%
LONG-TERM LIABILITIES
Long-Term Debt	$33.17B	$10.32B	$9.601B
YoY Change	221.58%	5.89%	31.27%
Other Long-Term Liabilities	$1.819B	$235.0M	$2.286B
YoY Change	674.04%	-89.31%	3.81%
Total Long-Term Liabilities	$34.99B	$235.0M	$11.89B
YoY Change	14789.36%	-98.03%	24.92%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.173B	$5.559B	$5.632B
Total Long-Term Liabilities	$34.99B	$235.0M	$11.89B
Total Liabilities	$53.46B	$18.50B	$17.88B
YoY Change	188.95%	13.99%	4.46%
SHAREHOLDERS EQUITY
Retained Earnings	$54.41B	$19.94B
YoY Change	172.89%
Common Stock	$0.00	$100.0M
YoY Change	-100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$53.23B	$19.44B	$19.35B
YoY Change
Total Liabilities & Shareholders Equity	$106.7B	$37.94B	$37.23B
YoY Change	181.17%	8.72%	6.53%

Cashflow Statement

Concept	2015 Q2	2014 Q2	2014 Q1
OPERATING ACTIVITIES
Net Income	-$1.000M	$448.0M	$762.0M
YoY Change	-100.22%	-53.77%	-22.87%
Depreciation, Depletion And Amortization	$677.0M	$215.0M	$214.0M
YoY Change	214.88%	2.87%	0.0%
Cash From Operating Activities	$1.912B	$1.328B	$1.612B
YoY Change	43.98%	4.57%	11.48%
INVESTING ACTIVITIES
Capital Expenditures	-$255.0M	-$105.0M	-$95.00M
YoY Change	142.86%	-13.22%	-24.0%
Acquisitions
YoY Change
Other Investing Activities	-$14.96B	-$420.0M	-$1.122B
YoY Change	3461.9%	-9.87%	-23.26%
Cash From Investing Activities	-$15.22B	-$525.0M	-$1.217B
YoY Change	2798.1%	-10.56%	-23.31%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.151B	-717.0M	-142.0M
YoY Change	-260.53%	-24.68%	-63.31%
NET CHANGE
Cash From Operating Activities	1.912B	1.328B	1.612B
Cash From Investing Activities	-15.22B	-525.0M	-1.217B
Cash From Financing Activities	1.151B	-717.0M	-142.0M
Net Change In Cash	-12.15B	86.00M	253.0M
YoY Change	-14230.23%	-131.97%	-147.92%
FREE CASH FLOW
Cash From Operating Activities	$1.912B	$1.328B	$1.612B
Capital Expenditures	-$255.0M	-$105.0M	-$95.00M
Free Cash Flow	$2.167B	$1.433B	$1.707B
YoY Change	51.22%	3.02%	8.66%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015	dei	Amendment Flag AmendmentFlag	false
CY2015	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--04-24
CY2015	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2015	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2015	dei	Document Period End Date DocumentPeriodEndDate	2015-04-24
CY2014	mdt	Acquisition Related Gains Charges AcquisitionRelatedGainsCharges	117000000	USD
CY2015	mdt	Acquisition Related Gains Charges AcquisitionRelatedGainsCharges	550000000	USD
CY2014Q2	mdt	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Unrealized Losses AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerUnrealizedLosses	18000000	USD
CY2015	dei	Document Type DocumentType	10-K
CY2015	dei	Entity Central Index Key EntityCentralIndexKey	0001613103
CY2015Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1416351117	shares
CY2015	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2015	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2014Q4	dei	Entity Public Float EntityPublicFloat	65400000000	USD
CY2015	dei	Entity Registrant Name EntityRegistrantName	Medtronic plc
CY2015	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2015	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2013	mdt	Acquisition Related Gains Charges AcquisitionRelatedGainsCharges	-49000000	USD
CY2015Q2	mdt	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Unrealized Losses AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerUnrealizedLosses	52000000	USD
CY2014Q2	mdt	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Unrealized Losses AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsUnrealizedLosses	90000000	USD
CY2015Q2	mdt	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Unrealized Losses AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsUnrealizedLosses	141000000	USD
CY2013	mdt	Business Acquisition Contingent Consideration Cash Payment BusinessAcquisitionContingentConsiderationCashPayment	18000000	USD
CY2014	mdt	Business Acquisition Contingent Consideration Cash Payment BusinessAcquisitionContingentConsiderationCashPayment	1000000	USD
CY2015	mdt	Business Acquisition Contingent Consideration Cash Payment BusinessAcquisitionContingentConsiderationCashPayment	85000000	USD
CY2014	mdt	Business Acquisition Contingent Consideration Milestone Payment BusinessAcquisitionContingentConsiderationMilestonePayment	1000000	USD
CY2015	mdt	Business Acquisition Contingent Consideration Milestone Payment BusinessAcquisitionContingentConsiderationMilestonePayment	85000000	USD
CY2014	mdt	Business Acquisition Purchase Price Contingent Consideration BusinessAcquisitionPurchasePriceContingentConsideration	65000000	USD
CY2015	mdt	Business Acquisition Purchase Price Contingent Consideration BusinessAcquisitionPurchasePriceContingentConsideration	40000000	USD
CY2013	mdt	Cash Advance Paidin Connection With Proposed Settlements CashAdvancePaidinConnectionWithProposedSettlements	0	USD
CY2014	mdt	Cash Advance Paidin Connection With Proposed Settlements CashAdvancePaidinConnectionWithProposedSettlements	0	USD
CY2015	mdt	Cash Advance Paidin Connection With Proposed Settlements CashAdvancePaidinConnectionWithProposedSettlements	378000000	USD
CY2014	mdt	Charitable Cash Contribution CharitableCashContribution	40000000	USD
CY2015	mdt	Charitable Cash Contribution CharitableCashContribution	100000000	USD
CY2014	mdt	Contingent Consideration Liability Acquired During Period ContingentConsiderationLiabilityAcquiredDuringPeriod	0	USD
CY2015	mdt	Contingent Consideration Liability Acquired During Period ContingentConsiderationLiabilityAcquiredDuringPeriod	236000000	USD
CY2014Q2	mdt	Cost And Equity Method Investment Without Quoted Market Price CostAndEquityMethodInvestmentWithoutQuotedMarketPrice	666000000	USD
CY2015Q2	mdt	Cost And Equity Method Investment Without Quoted Market Price CostAndEquityMethodInvestmentWithoutQuotedMarketPrice	520000000	USD
CY2015Q2	mdt	Deferred Stock Paror Stated Value Per Share DeferredStockParorStatedValuePerShare	1.00
CY2015Q2	mdt	Deferred Stock Shares Authorized DeferredStockSharesAuthorized	40000	shares
CY2014Q2	mdt	Deferred Tax Assets Operating And Capital Losses And Tax Credit Carryforwards DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards	487000000	USD
CY2015Q2	mdt	Deferred Tax Assets Operating And Capital Losses And Tax Credit Carryforwards DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards	5912000000	USD
CY2015Q2	mdt	Deferred Tax Assets Tax Credit Carryforwards Not Subjectto Expiration DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration	102000000	USD
CY2014Q2	mdt	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Postretirement Benefits And Pensions DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefitsAndPensions	194000000	USD
CY2015Q2	mdt	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Postretirement Benefits And Pensions DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefitsAndPensions	449000000	USD
CY2014Q2	mdt	Deferred Tax Assetstax Deferred Expense Federal And State Benefit On Uncertain Tax Positions DeferredTaxAssetstaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions	79000000	USD
CY2015Q2	mdt	Deferred Tax Assetstax Deferred Expense Federal And State Benefit On Uncertain Tax Positions DeferredTaxAssetstaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions	296000000	USD
CY2014Q2	mdt	Deferred Tax Liabilities Unrealized Gains On Available For Sale Securities And Derivative Financial Instruments DeferredTaxLiabilitiesUnrealizedGainsOnAvailableForSaleSecuritiesAndDerivativeFinancialInstruments	0	USD
CY2015Q2	mdt	Deferred Tax Liabilities Unrealized Gains On Available For Sale Securities And Derivative Financial Instruments DeferredTaxLiabilitiesUnrealizedGainsOnAvailableForSaleSecuritiesAndDerivativeFinancialInstruments	160000000	USD
CY2015	mdt	Defined Contribution Plan Treasury Bond Rate Of Guaranteed Rate Of Return DefinedContributionPlanTreasuryBondRateOfGuaranteedRateOfReturn	P10Y
CY2014Q2	mdt	Derivative Assets And Liabilities Net Collateral Rightto Reclaim Securities DerivativeAssetsAndLiabilitiesNetCollateralRighttoReclaimSecurities	0	USD
CY2015Q2	mdt	Derivative Assets And Liabilities Net Collateral Rightto Reclaim Securities DerivativeAssetsAndLiabilitiesNetCollateralRighttoReclaimSecurities	0	USD
CY2014Q2	mdt	Derivative Assetsand Liabilities Net Collateral Obligationto Return Cash DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash	0	USD
CY2015Q2	mdt	Derivative Assetsand Liabilities Net Collateral Obligationto Return Cash DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash	330000000	USD
CY2013	mdt	Effective Income Tax Rate Reconciliation Puerto Rico Excise Tax EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax	-0.013
CY2014	mdt	Effective Income Tax Rate Reconciliation Puerto Rico Excise Tax EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax	-0.016
CY2015	mdt	Effective Income Tax Rate Reconciliation Puerto Rico Excise Tax EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax	-0.017
CY2013	mdt	Effective Income Tax Rate Reconciliation Reversal Of Excess Tax Accruals EffectiveIncomeTaxRateReconciliationReversalOfExcessTaxAccruals	0.000
CY2014	mdt	Effective Income Tax Rate Reconciliation Reversal Of Excess Tax Accruals EffectiveIncomeTaxRateReconciliationReversalOfExcessTaxAccruals	0.019
CY2015	mdt	Effective Income Tax Rate Reconciliation Reversal Of Excess Tax Accruals EffectiveIncomeTaxRateReconciliationReversalOfExcessTaxAccruals	0.000
CY2014Q2	mdt	In Process Research And Development InProcessResearchAndDevelopment	119000000	USD
CY2015Q2	mdt	In Process Research And Development InProcessResearchAndDevelopment	470000000	USD
CY2013	mdt	Increase Decrease In Intercompany Receivable IncreaseDecreaseInIntercompanyReceivable	0	USD
CY2014	mdt	Increase Decrease In Intercompany Receivable IncreaseDecreaseInIntercompanyReceivable	0	USD
CY2015	mdt	Increase Decrease In Intercompany Receivable IncreaseDecreaseInIntercompanyReceivable	0	USD
CY2013	mdt	Increase Decreasein Intercompany Payable IncreaseDecreaseinIntercompanyPayable	0	USD
CY2014	mdt	Increase Decreasein Intercompany Payable IncreaseDecreaseinIntercompanyPayable	0	USD
CY2015	mdt	Increase Decreasein Intercompany Payable IncreaseDecreaseinIntercompanyPayable	0	USD
CY2013	mdt	Increasein Investmentin Subsidiary IncreaseinInvestmentinSubsidiary	0	USD
CY2014	mdt	Increasein Investmentin Subsidiary IncreaseinInvestmentinSubsidiary	0	USD
CY2013	mdt	Incremental Common Shares Attributable To Employee Restricted Stock Awards And Units IncrementalCommonSharesAttributableToEmployeeRestrictedStockAwardsAndUnits	5300000	shares
CY2014	mdt	Incremental Common Shares Attributable To Employee Restricted Stock Awards And Units IncrementalCommonSharesAttributableToEmployeeRestrictedStockAwardsAndUnits	4300000	shares
CY2015	mdt	Incremental Common Shares Attributable To Employee Restricted Stock Awards And Units IncrementalCommonSharesAttributableToEmployeeRestrictedStockAwardsAndUnits	4300000	shares
CY2013	mdt	Incremental Common Shares Attributable To Employee Stock Options IncrementalCommonSharesAttributableToEmployeeStockOptions	2800000	shares
CY2014	mdt	Incremental Common Shares Attributable To Employee Stock Options IncrementalCommonSharesAttributableToEmployeeStockOptions	7100000	shares
CY2015	mdt	Incremental Common Shares Attributable To Employee Stock Options IncrementalCommonSharesAttributableToEmployeeStockOptions	9100000	shares
CY2013	mdt	Incremental Common Shares Attributable To Other Adjustments IncrementalCommonSharesAttributableToOtherAdjustments	100000	shares
CY2014	mdt	Incremental Common Shares Attributable To Other Adjustments IncrementalCommonSharesAttributableToOtherAdjustments	100000	shares
CY2015	mdt	Incremental Common Shares Attributable To Other Adjustments IncrementalCommonSharesAttributableToOtherAdjustments	100000	shares
CY2015	mdt	Intercompany Dividends Paid IntercompanyDividendsPaid	0	USD
CY2014Q2	mdt	Intercompany Payable Current IntercompanyPayableCurrent	0	USD
CY2015Q2	mdt	Intercompany Payable Current IntercompanyPayableCurrent	0	USD
CY2014Q2	mdt	Intercompany Payable Noncurrent IntercompanyPayableNoncurrent	0	USD
CY2015Q2	mdt	Intercompany Payable Noncurrent IntercompanyPayableNoncurrent	0	USD
CY2014Q2	mdt	Intercompany Receivable Current IntercompanyReceivableCurrent	0	USD
CY2015Q2	mdt	Intercompany Receivable Current IntercompanyReceivableCurrent	0	USD
CY2014Q2	mdt	Intercompany Receivable Noncurrent IntercompanyReceivableNoncurrent	0	USD
CY2015Q2	mdt	Intercompany Receivable Noncurrent IntercompanyReceivableNoncurrent	0	USD
CY2014Q2	mdt	Investmentin Subsidiaries InvestmentinSubsidiaries	0	USD
CY2015Q2	mdt	Investmentin Subsidiaries InvestmentinSubsidiaries	0	USD
CY2014Q2	mdt	Long Term Debt Face Amount LongTermDebtFaceAmount	11375000000	USD
CY2015Q2	mdt	Long Term Debt Face Amount LongTermDebtFaceAmount	32125000000	USD
CY2013	mdt	Noncash Acquisition Related Gains Charges NoncashAcquisitionRelatedGainsCharges	-74000000	USD
CY2014	mdt	Noncash Acquisition Related Gains Charges NoncashAcquisitionRelatedGainsCharges	110000000	USD
CY2015	mdt	Noncash Acquisition Related Gains Charges NoncashAcquisitionRelatedGainsCharges	634000000	USD
CY2015	mdt	Reclassificationfrom Accumulated Other Comprehensive Income Current Period Tax ReclassificationfromAccumulatedOtherComprehensiveIncomeCurrentPeriodTax	-77000000	USD
CY2015	mdt	Numberof Operating Geographic Regions NumberofOperatingGeographicRegions	4	region
CY2014	mdt	Other Comprehensive Income Loss Before Reclassifications Tax OtherComprehensiveIncomeLossBeforeReclassificationsTax	-39000000	USD
CY2015	mdt	Other Comprehensive Income Loss Before Reclassifications Tax OtherComprehensiveIncomeLossBeforeReclassificationsTax	61000000	USD
CY2013	mdt	Other Comprehensive Income Loss Derivatives Qualifying As Hedges Transfers Between Classifications Increase Decrease Net Of Tax OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTransfersBetweenClassificationsIncreaseDecreaseNetOfTax	80000000	USD
CY2013	mdt	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Transfers Between Classifications Increase Decrease Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationTransfersBetweenClassificationsIncreaseDecreaseNetOfTax	-80000000	USD
CY2014	mdt	Reclassificationfrom Accumulated Other Comprehensive Income Current Period Tax ReclassificationfromAccumulatedOtherComprehensiveIncomeCurrentPeriodTax	-7000000	USD
CY2013	mdt	Restructuring Charges Netof Restructuring Reversals RestructuringChargesNetofRestructuringReversals	172000000	USD
CY2014	mdt	Restructuring Charges Netof Restructuring Reversals RestructuringChargesNetofRestructuringReversals	78000000	USD
CY2015	mdt	Restructuring Charges Netof Restructuring Reversals RestructuringChargesNetofRestructuringReversals	237000000	USD
CY2013	mdt	Special Charges SpecialCharges	0	USD
CY2014	mdt	Special Charges SpecialCharges	40000000	USD
CY2015	mdt	Special Charges SpecialCharges	-38000000	USD
CY2013	mdt	Stock Issued During Period Value Share Based Compensation8 StockIssuedDuringPeriodValueShareBasedCompensation8	267000000	USD
CY2014	mdt	Stock Issued During Period Value Share Based Compensation8 StockIssuedDuringPeriodValueShareBasedCompensation8	1307000000	USD
CY2015	mdt	Stock Issued During Period Value Share Based Compensation8 StockIssuedDuringPeriodValueShareBasedCompensation8	649000000	USD
CY2015	mdt	Stock Issued To Advisors During Period Shares New Issues StockIssuedToAdvisorsDuringPeriodSharesNewIssues	624	shares
CY2014	mdt	Stock Repurchase Program Average Purchase Price StockRepurchaseProgramAveragePurchasePrice	53.37
CY2015	mdt	Stock Repurchase Program Average Purchase Price StockRepurchaseProgramAveragePurchasePrice	64.53
CY2014Q2	mdt	Unrealized Gain Loss On Interest Rate Cash Flow Hedges Accumulated Other Comprehensive Income Loss Net Of Tax UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax	-44000000	USD
CY2015Q2	mdt	Unrealized Gain Loss On Interest Rate Cash Flow Hedges Accumulated Other Comprehensive Income Loss Net Of Tax UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax	210000000	USD
CY2013Q2	mdt	Unrecognized Tax Benefits Netof Cash Advance Paid UnrecognizedTaxBenefitsNetofCashAdvancePaid	1068000000	USD
CY2014Q2	mdt	Unrecognized Tax Benefits Netof Cash Advance Paid UnrecognizedTaxBenefitsNetofCashAdvancePaid	1172000000	USD
CY2015Q2	mdt	Unrecognized Tax Benefits Netof Cash Advance Paid UnrecognizedTaxBenefitsNetofCashAdvancePaid	2482000000	USD
CY2014Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	742000000	USD
CY2015Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1610000000	USD
CY2014Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3811000000	USD
CY2015Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5112000000	USD
CY2014Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	164000000	USD
CY2015Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	935000000	USD
CY2014Q2	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	1343000000	USD
CY2015Q2	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	2476000000	USD
CY2014Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4047000000	USD
CY2015Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4164000000	USD
CY2012Q2	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	130000000	USD
CY2013Q2	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	97000000	USD
CY2012Q2	us-gaap	Accumulated Other Comprehensive Income Loss Cumulative Changes In Net Gain Loss From Cash Flow Hedges Effect Net Of Tax AccumulatedOtherComprehensiveIncomeLossCumulativeChangesInNetGainLossFromCashFlowHedgesEffectNetOfTax	-75000000	USD
CY2013Q2	us-gaap	Accumulated Other Comprehensive Income Loss Cumulative Changes In Net Gain Loss From Cash Flow Hedges Effect Net Of Tax AccumulatedOtherComprehensiveIncomeLossCumulativeChangesInNetGainLossFromCashFlowHedgesEffectNetOfTax	58000000	USD
CY2012Q2	us-gaap	Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax	834000000	USD
CY2013Q2	us-gaap	Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax	852000000	USD
CY2012Q2	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	306000000	USD
CY2013Q2	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	205000000	USD
CY2012Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-473000000	USD
CY2013Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-492000000	USD
CY2014Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-597000000	USD
CY2015Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1184000000	USD
CY2013	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	-7000000	USD
CY2014	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	29000000	USD
CY2015	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	81000000	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	152000000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	145000000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	439000000	USD
CY2013	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	152000000	USD
CY2014	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	145000000	USD
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	439000000	USD
CY2013	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	109000000	USD
CY2014	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	105000000	USD
CY2015	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	301000000	USD
CY2014Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	115000000	USD
CY2015Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	144000000	USD
CY2013	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	104000000	USD
CY2014	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	8000000	USD
CY2015	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	76000000	USD
CY2013	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	331000000	USD
CY2014	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	349000000	USD
CY2015	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	733000000	USD
CY2014Q2	us-gaap	Assets Assets	37943000000	USD
CY2015Q2	us-gaap	Assets Assets	106685000000	USD
CY2014Q2	us-gaap	Assets Current AssetsCurrent	21210000000	USD
CY2015Q2	us-gaap	Assets Current AssetsCurrent	30844000000	USD
CY2014Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	5032000000	USD
CY2015Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	2941000000	USD
CY2014Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	221000000	USD
CY2015Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	1171000000	USD
CY2015Q2	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	3097000000	USD
CY2015Q2	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	6646000000	USD
CY2015Q2	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	182000000	USD
CY2015Q2	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	1812000000	USD
CY2015Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	11737000000	USD
CY2014	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	3280000000	USD
CY2015	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	3944000000	USD
CY2014	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	27380000000	USD
CY2015	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	28369000000	USD
CY2014	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-138000000	USD
CY2015	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	5000000	USD
CY2013Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	142000000	USD
CY2014Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	68000000	USD
CY2015Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	264000000	USD
CY2015Q2	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	167000000	USD
CY2015Q2	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	20000000	USD
CY2015Q2	us-gaap	Capital Leases Future Minimum Payments Due In Five Years CapitalLeasesFutureMinimumPaymentsDueInFiveYears	22000000	USD
CY2015Q2	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	22000000	USD
CY2015Q2	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	23000000	USD
CY2015Q2	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	37000000	USD
CY2015Q2	us-gaap	Capital Leases Future Minimum Payments Due Thereafter CapitalLeasesFutureMinimumPaymentsDueThereafter	43000000	USD
CY2015Q2	us-gaap	Capital Leases Future Minimum Payments Interest Included In Payments CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments	22000000	USD
CY2015Q2	us-gaap	Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments	145000000	USD
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1172000000	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	919000000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1403000000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4843000000	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-253000000	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	484000000	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	3440000000	USD
CY2015	us-gaap	Cash Flow Hedge Gain Loss To Be Reclassified Within Twelve Months CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths	230000000	USD
CY2014Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	1.04
CY2014	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	1.12
CY2015	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	1.22
CY2014Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.10
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2014Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1600000000	shares
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2600000000	shares
CY2014Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	998999125	shares
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1421648005	shares
CY2014Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	998999125	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1421648005	shares
CY2014Q2	us-gaap	Common Stock Value CommonStockValue	100000000	USD
CY2015Q2	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2013	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	3448000000	USD
CY2014	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2960000000	USD
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2088000000	USD
CY2013	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4126000000	USD
CY2014	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4333000000	USD
CY2015	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	6309000000	USD
CY2013	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	509000000	USD
CY2014	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	532000000	USD
CY2015	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	1128000000	USD
CY2013	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	219000000	USD
CY2014	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	248000000	USD
CY2015	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	502000000	USD
CY2013	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	728000000	USD
CY2014	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	780000000	USD
CY2015	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1630000000	USD
CY2014Q2	us-gaap	Debt Current DebtCurrent	1613000000	USD
CY2015Q2	us-gaap	Debt Current DebtCurrent	2434000000	USD
CY2015Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	35590000000	USD
CY2014Q2	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	25000000	USD
CY2015Q2	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	-499000000	USD
CY2014Q2	us-gaap	Debt Instrument Unamortized Premium DebtInstrumentUnamortizedPremium	0	USD
CY2015Q2	us-gaap	Debt Instrument Unamortized Premium DebtInstrumentUnamortizedPremium	5000000	USD
CY2014Q2	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	1015000000	USD
CY2015Q2	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	1611000000	USD
CY2013	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	46000000	USD
CY2014	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-175000000	USD
CY2015	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-705000000	USD
CY2013	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	10000000	USD
CY2014	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	35000000	USD
CY2015	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-114000000	USD
CY2014Q2	us-gaap	Deferred Gain Loss On Discontinuation Of Interest Rate Fair Value Hedge DeferredGainLossOnDiscontinuationOfInterestRateFairValueHedge	-20000000	USD
CY2015Q2	us-gaap	Deferred Gain Loss On Discontinuation Of Interest Rate Fair Value Hedge DeferredGainLossOnDiscontinuationOfInterestRateFairValueHedge	-3000000	USD
CY2013	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	56000000	USD
CY2014	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-140000000	USD
CY2015	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-819000000	USD
CY2013	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-7000000	USD
CY2014	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-207000000	USD
CY2015	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-926000000	USD
CY2014Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1626000000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	8464000000	USD
CY2014Q2	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	118000000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	171000000	USD
CY2014Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	631000000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	-2710000000	USD
CY2014Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1229000000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	2857000000	USD
CY2014Q2	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	736000000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	1335000000	USD
CY2014Q2	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	300000000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	774000000	USD
CY2014Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	171000000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	303000000	USD
CY2014Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	201000000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	330000000	USD
CY2014Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	171000000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	418000000	USD
CY2015Q2	us-gaap	Derivative Collateral Obligation To Return Cash DerivativeCollateralObligationToReturnCash	338000000	USD
CY2014Q2	us-gaap	Derivative Collateral Obligation To Return Securities DerivativeCollateralObligationToReturnSecurities	95000000	USD
CY2014Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	205000000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	585000000	USD
CY2014Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	397000000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5607000000	USD
CY2014Q2	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	1031000000	USD
CY2015Q2	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	6182000000	USD
CY2014Q2	us-gaap	Deferred Tax Liabilities Current DeferredTaxLiabilitiesCurrent	19000000	USD
CY2015Q2	us-gaap	Deferred Tax Liabilities Current DeferredTaxLiabilitiesCurrent	119000000	USD
CY2014Q2	us-gaap	Deferred Tax Liabilities Derivatives DeferredTaxLiabilitiesDerivatives	110000000	USD
CY2015Q2	us-gaap	Deferred Tax Liabilities Derivatives DeferredTaxLiabilitiesDerivatives	112000000	USD
CY2014Q2	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	652000000	USD
CY2015Q2	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	5393000000	USD
CY2014Q2	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	386000000	USD
CY2015Q2	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	4700000000	USD
CY2014Q2	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	24000000	USD
CY2015Q2	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	96000000	USD
CY2014Q2	us-gaap	Deferred Tax Liabilities Parents Basis In Discontinued Operation DeferredTaxLiabilitiesParentsBasisInDiscontinuedOperation	225000000	USD
CY2015Q2	us-gaap	Deferred Tax Liabilities Parents Basis In Discontinued Operation DeferredTaxLiabilitiesParentsBasisInDiscontinuedOperation	204000000	USD
CY2014Q2	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	20000000	USD
CY2015Q2	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	217000000	USD
CY2014Q2	us-gaap	Defined Benefit Plan Funded Status Of Plan DefinedBenefitPlanFundedStatusOfPlan	-488000000	USD
CY2015Q2	us-gaap	Defined Benefit Plan Funded Status Of Plan DefinedBenefitPlanFundedStatusOfPlan	-1274000000	USD
CY2014Q2	us-gaap	Defined Benefit Plan Pension Plans With Accumulated Benefit Obligations In Excess Of Plan Assets Aggregate Accumulated Benefit Obligation DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation	2426000000	USD
CY2015Q2	us-gaap	Defined Benefit Plan Pension Plans With Accumulated Benefit Obligations In Excess Of Plan Assets Aggregate Accumulated Benefit Obligation DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation	3678000000	USD
CY2014Q2	us-gaap	Defined Benefit Plan Pension Plans With Accumulated Benefit Obligations In Excess Of Plan Assets Aggregate Fair Value Of Plan Assets DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets	2268000000	USD
CY2015Q2	us-gaap	Defined Benefit Plan Pension Plans With Accumulated Benefit Obligations In Excess Of Plan Assets Aggregate Fair Value Of Plan Assets DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets	2823000000	USD
CY2014Q2	us-gaap	Defined Benefit Plan Pension Plans With Accumulated Benefit Obligations In Excess Of Plan Assets Aggregate Projected Benefit Obligation DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation	2703000000	USD
CY2015Q2	us-gaap	Defined Benefit Plan Pension Plans With Accumulated Benefit Obligations In Excess Of Plan Assets Aggregate Projected Benefit Obligation DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation	4032000000	USD
CY2014Q2	us-gaap	Defined Benefit Plan Plans With Benefit Obligations In Excess Of Plan Assets Aggregate Benefit Obligation DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAggregateBenefitObligation	2864000000	USD
CY2015Q2	us-gaap	Defined Benefit Plan Plans With Benefit Obligations In Excess Of Plan Assets Aggregate Benefit Obligation DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAggregateBenefitObligation	4319000000	USD
CY2014Q2	us-gaap	Defined Benefit Plan Plans With Benefit Obligations In Excess Of Plan Assets Aggregate Fair Value Of Plan Assets DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets	2419000000	USD
CY2015Q2	us-gaap	Defined Benefit Plan Plans With Benefit Obligations In Excess Of Plan Assets Aggregate Fair Value Of Plan Assets DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets	3086000000	USD
CY2015	us-gaap	Defined Benefit Plans Estimated Future Employer Contributions In Next Fiscal Year DefinedBenefitPlansEstimatedFutureEmployerContributionsInNextFiscalYear	79000000	USD
CY2013	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	163000000	USD
CY2014	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	145000000	USD
CY2015	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	188000000	USD
CY2013	us-gaap	Depreciation Depreciation	488000000	USD
CY2014	us-gaap	Depreciation Depreciation	501000000	USD
CY2015	us-gaap	Depreciation Depreciation	573000000	USD
CY2013	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	819000000	USD
CY2014	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	850000000	USD
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1306000000	USD
CY2014Q2	us-gaap	Derivative Collateral Obligation To Return Cash DerivativeCollateralObligationToReturnCash	0	USD
CY2015Q2	us-gaap	Derivative Collateral Obligation To Return Securities DerivativeCollateralObligationToReturnSecurities	71000000	USD
CY2014Q2	us-gaap	Derivative Collateral Right To Reclaim Cash DerivativeCollateralRightToReclaimCash	0	USD
CY2015Q2	us-gaap	Derivative Collateral Right To Reclaim Cash DerivativeCollateralRightToReclaimCash	8000000	USD
CY2014Q2	us-gaap	Derivative Collateral Right To Reclaim Securities DerivativeCollateralRightToReclaimSecurities	95000000	USD
CY2015Q2	us-gaap	Derivative Collateral Right To Reclaim Securities DerivativeCollateralRightToReclaimSecurities	71000000	USD
CY2014Q2	us-gaap	Derivative Fair Value Amount Offset Against Collateral Net DerivativeFairValueAmountOffsetAgainstCollateralNet	48000000	USD
CY2015Q2	us-gaap	Derivative Fair Value Amount Offset Against Collateral Net DerivativeFairValueAmountOffsetAgainstCollateralNet	287000000	USD
CY2014Q2	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	175000000	USD
CY2015Q2	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	733000000	USD
CY2014Q2	us-gaap	Derivative Fair Value Of Derivative Asset Amount Not Offset Against Collateral DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral	48000000	USD
CY2015Q2	us-gaap	Derivative Fair Value Of Derivative Asset Amount Not Offset Against Collateral DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral	617000000	USD
CY2014Q2	us-gaap	Derivative Fair Value Of Derivative Asset Amount Offset Against Collateral DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral	80000000	USD
CY2015Q2	us-gaap	Derivative Fair Value Of Derivative Asset Amount Offset Against Collateral DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral	324000000	USD
CY2014Q2	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	127000000	USD
CY2015Q2	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	116000000	USD
CY2014Q2	us-gaap	Derivative Fair Value Of Derivative Liability Amount Offset Against Collateral DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral	32000000	USD
CY2015Q2	us-gaap	Derivative Fair Value Of Derivative Liability Amount Offset Against Collateral DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral	37000000	USD
CY2013	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	1055000000	USD
CY2014	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	1116000000	USD
CY2015	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	1337000000	USD
CY2013	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.40
CY2013Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.94
CY2013Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.90
CY2014Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.76
CY2014Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.45
CY2014	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.06
CY2014Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.88
CY2014Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.84
CY2015Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.99
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2015	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.44
CY2013	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.37
CY2013Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.93
CY2013Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.89
CY2014Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.75
CY2014Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.44
CY2014	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.02
CY2014Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.87
CY2014Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.83
CY2015Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.98
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2015	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.41
CY2013	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	7000000	USD
CY2014	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	37000000	USD
CY2015	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-353000000	USD
CY2013	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.184
CY2014	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.173
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.233
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Deductions Qualified Production Activities EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities	0.003
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Deductions Qualified Production Activities EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities	0.004
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Deductions Qualified Production Activities EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities	0.004
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.167
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.177
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.243
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.020
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.056
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.133
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.003
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.018
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.013
CY2013	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.005
CY2014	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.006
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.008
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.011
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.005
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.007
CY2013	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	43000000	USD
CY2014	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	40000000	USD
CY2015	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	138000000	USD
CY2015	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	97000000	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2298000000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2948000000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1911000000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1717000000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1765000000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1858000000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1889000000	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	4465000000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	30329000000	USD
CY2015	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	138000000	USD
CY2013	us-gaap	Gain Loss On Foreign Currency Derivatives Recorded In Earnings Net GainLossOnForeignCurrencyDerivativesRecordedInEarningsNet	25000000	USD
CY2014	us-gaap	Gain Loss On Foreign Currency Derivatives Recorded In Earnings Net GainLossOnForeignCurrencyDerivativesRecordedInEarningsNet	-1000000	USD
CY2015	us-gaap	Gain Loss On Foreign Currency Derivatives Recorded In Earnings Net GainLossOnForeignCurrencyDerivativesRecordedInEarningsNet	131000000	USD
CY2015	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	41000000	USD
CY2013Q2	us-gaap	Goodwill Goodwill	10329000000	USD
CY2014Q2	us-gaap	Goodwill Goodwill	10593000000	USD
CY2015Q2	us-gaap	Goodwill Goodwill	40530000000	USD
CY2014	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	279000000	USD
CY2014	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	-1000000	USD
CY2015	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	-9000000	USD
CY2014	us-gaap	Goodwill Translation Adjustments GoodwillTranslationAdjustments	-14000000	USD
CY2015	us-gaap	Goodwill Translation Adjustments GoodwillTranslationAdjustments	-112000000	USD
CY2013Q3	us-gaap	Gross Profit GrossProfit	3061000000	USD
CY2013Q4	us-gaap	Gross Profit GrossProfit	3104000000	USD
CY2014Q1	us-gaap	Gross Profit GrossProfit	3113000000	USD
CY2014Q2	us-gaap	Gross Profit GrossProfit	3395000000	USD
CY2014	us-gaap	Gross Profit GrossProfit	12672000000	USD
CY2014Q3	us-gaap	Gross Profit GrossProfit	3168000000	USD
CY2014Q4	us-gaap	Gross Profit GrossProfit	3224000000	USD
CY2015Q1	us-gaap	Gross Profit GrossProfit	3190000000	USD
CY2015Q2	us-gaap	Gross Profit GrossProfit	4370000000	USD
CY2015	us-gaap	Gross Profit GrossProfit	13952000000	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	1806000000	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	1690000000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	639000000	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	2445000000	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	2015000000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	2847000000	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	4251000000	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	3705000000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	3486000000	USD
CY2013	us-gaap	Income Loss From Subsidiaries Net Of Tax IncomeLossFromSubsidiariesNetOfTax	0	USD
CY2014	us-gaap	Income Loss From Subsidiaries Net Of Tax IncomeLossFromSubsidiariesNetOfTax	0	USD
CY2015	us-gaap	Income Loss From Subsidiaries Net Of Tax IncomeLossFromSubsidiariesNetOfTax	0	USD
CY2015Q2	us-gaap	Income Tax Examination Estimate Of Possible Loss IncomeTaxExaminationEstimateOfPossibleLoss	329000000	USD
CY2013	us-gaap	Income Tax Examination Interest Expense IncomeTaxExaminationInterestExpense	33000000	USD
CY2014	us-gaap	Income Tax Examination Interest Expense IncomeTaxExaminationInterestExpense	36000000	USD
CY2015	us-gaap	Income Tax Examination Interest Expense IncomeTaxExaminationInterestExpense	142000000	USD
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	784000000	USD
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	640000000	USD
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	811000000	USD
CY2014Q2	us-gaap	Income Tax Receivable IncomeTaxReceivable	113000000	USD
CY2015Q2	us-gaap	Income Tax Receivable IncomeTaxReceivable	188000000	USD
CY2015	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	71000000	USD
CY2015	us-gaap	Income Tax Reconciliation Tax Settlements Domestic IncomeTaxReconciliationTaxSettlementsDomestic	63000000	USD
CY2013	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	537000000	USD
CY2014	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	521000000	USD
CY2015	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	632000000	USD
CY2013	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	-1000000	USD
CY2014	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	70000000	USD
CY2015	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	413000000	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	481000000	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-117000000	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1616000000	USD
CY2013	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-93000000	USD
CY2014	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	39000000	USD
CY2015	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	282000000	USD
CY2013	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	215000000	USD
CY2014	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-444000000	USD
CY2015	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-643000000	USD
CY2014Q2	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	119000000	USD
CY2015Q2	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	720000000	USD
CY2014Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2286000000	USD
CY2015Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	28101000000	USD
CY2013	us-gaap	Interest Expense InterestExpense	388000000	USD
CY2014	us-gaap	Interest Expense InterestExpense	379000000	USD
CY2015	us-gaap	Interest Expense InterestExpense	666000000	USD
CY2013	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-151000000	USD
CY2014	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-108000000	USD
CY2015	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-280000000	USD
CY2013	us-gaap	Interest Income Other InterestIncomeOther	237000000	USD
CY2014	us-gaap	Interest Income Other InterestIncomeOther	271000000	USD
CY2015	us-gaap	Interest Income Other InterestIncomeOther	386000000	USD
CY2013	us-gaap	Interest Paid InterestPaid	333000000	USD
CY2014	us-gaap	Interest Paid InterestPaid	394000000	USD
CY2015	us-gaap	Interest Paid InterestPaid	578000000	USD
CY2014Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1196000000	USD
CY2015Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2268000000	USD
CY2014Q2	us-gaap	Inventory Net InventoryNet	1725000000	USD
CY2015Q2	us-gaap	Inventory Net InventoryNet	3463000000	USD
CY2014Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	282000000	USD
CY2015Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	686000000	USD
CY2014Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	247000000	USD
CY2015Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	509000000	USD
CY2014Q2	us-gaap	Investment Owned At Cost InvestmentOwnedAtCost	13659000000	USD
CY2015Q2	us-gaap	Investment Owned At Cost InvestmentOwnedAtCost	15312000000	USD
CY2014Q2	us-gaap	Investment Owned Unrecognized Unrealized Appreciation InvestmentOwnedUnrecognizedUnrealizedAppreciation	108000000	USD
CY2015Q2	us-gaap	Investment Owned Unrecognized Unrealized Appreciation InvestmentOwnedUnrecognizedUnrealizedAppreciation	224000000	USD
CY2014Q2	us-gaap	Investment Owned Unrecognized Unrealized Depreciation InvestmentOwnedUnrecognizedUnrealizedDepreciation	108000000	USD
CY2015Q2	us-gaap	Investment Owned Unrecognized Unrealized Depreciation InvestmentOwnedUnrecognizedUnrealizedDepreciation	193000000	USD
CY2014Q2	us-gaap	Investments Investments	12993000000	USD
CY2015Q2	us-gaap	Investments Investments	14823000000	USD
CY2013	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	140000000	USD
CY2014	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	150000000	USD
CY2015	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	195000000	USD
CY2014Q2	us-gaap	Liabilities Liabilities	18500000000	USD
CY2015Q2	us-gaap	Liabilities Liabilities	53455000000	USD
CY2014Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	37943000000	USD
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	106685000000	USD
CY2014Q2	us-gaap	Liabilities Current LiabilitiesCurrent	5559000000	USD
CY2015Q2	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	2593000000	USD
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	9173000000	USD
CY2015Q2	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	267000000	USD
CY2014Q2	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	10315000000	USD
CY2015Q2	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	33752000000	USD
CY2015Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	2419000000	USD
CY2014Q2	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	11856000000	USD
CY2015Q2	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	34637000000	USD
CY2015Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	21764000000	USD
CY2015Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	2419000000	USD
CY2015Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	4273000000	USD
CY2015Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	423000000	USD
CY2015Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	6173000000	USD
CY2015Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	538000000	USD
CY2015Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	33171000000	USD
CY2014Q2	us-gaap	Long Term Investments LongTermInvestments	821000000	USD
CY2015Q2	us-gaap	Long Term Investments LongTermInvestments	706000000	USD
CY2014Q2	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	917000000	USD
CY2015Q2	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	879000000	USD
CY2013	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	245000000	USD
CY2014	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	770000000	USD
CY2015	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	42000000	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-2101000000	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-918000000	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	15949000000	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-3101000000	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-3594000000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-17058000000	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	4942000000	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	4959000000	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	4902000000	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	3467000000	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	953000000	USD
CY2013Q4	us-gaap	Net Income Loss NetIncomeLoss	902000000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	762000000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	448000000	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	3065000000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	871000000	USD
CY2014Q4	us-gaap	Net Income Loss NetIncomeLoss	828000000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	977000000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-1000000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	2675000000	USD
CY2013	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	3467000000	USD
CY2014	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	3065000000	USD
CY2015	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-118000000	USD
CY2015	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	4	segment
CY2015	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	4	segment
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	4402000000	USD
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	2675000000	USD
CY2013	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-108000000	USD
CY2014	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-181000000	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	3813000000	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	3766000000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	624000000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	196000000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	43000000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	66000000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	93000000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	138000000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	88000000	USD
CY2014Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1162000000	USD
CY2015Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1737000000	USD
CY2013	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-21000000	USD
CY2014	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	13000000	USD
CY2015	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-495000000	USD
CY2014	us-gaap	Other Comprehensive Income Loss Before Reclassifications Before Tax OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax	-136000000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Before Reclassifications Before Tax OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax	-398000000	USD
CY2014	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	-97000000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	-459000000	USD
CY2013	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-19000000	USD
CY2014	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-105000000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-587000000	USD
CY2013	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	18000000	USD
CY2014	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-87000000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	366000000	USD
CY2013	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax	-4000000	USD
CY2014	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax	72000000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax	-173000000	USD
CY2013	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	53000000	USD
CY2014	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-102000000	USD
CY2015	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	254000000	USD
CY2013	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax	30000000	USD
CY2014	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax	-60000000	USD
CY2015	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax	146000000	USD
CY2013	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-33000000	USD
CY2014	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-103000000	USD
CY2015	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	20000000	USD
CY2013	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	-19000000	USD
CY2014	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	-58000000	USD
CY2015	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	11000000	USD
CY2014Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2006000000	USD
CY2015Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2464000000	USD
CY2014Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	235000000	USD
CY2015Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1819000000	USD
CY2013	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
CY2014	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	10895000000	USD
CY2015	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	7582000000	USD
CY2014	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	28000000	USD
CY2015	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	134000000	USD
CY2013Q2	us-gaap	Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld	9000000	USD
CY2014Q2	us-gaap	Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld	4000000	USD
CY2014	us-gaap	Other Than Temporary Impairment Credit Losses Recognized In Earnings Reductions Securities Sold OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsReductionsSecuritiesSold	5000000	USD
CY2015	us-gaap	Other Than Temporary Impairment Credit Losses Recognized In Earnings Reductions Securities Sold OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsReductionsSecuritiesSold	4000000	USD
CY2013	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	175000000	USD
CY2014	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	15000000	USD
CY2015	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	809000000	USD
CY2013	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	14000000	USD
CY2014	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	29000000	USD
CY2015	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-89000000	USD
CY2013	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1247000000	USD
CY2014	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2553000000	USD
CY2015	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1920000000	USD
CY2013	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	1055000000	USD
CY2014	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	1116000000	USD
CY2015	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	1337000000	USD
CY2013	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	820000000	USD
CY2014	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	385000000	USD
CY2015	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	14884000000	USD
CY2013	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	12321000000	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	457000000	USD
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	396000000	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	571000000	USD
CY2013	us-gaap	Pension And Other Postretirement Benefit Expense PensionAndOtherPostretirementBenefitExpense	419000000	USD
CY2014	us-gaap	Pension And Other Postretirement Benefit Expense PensionAndOtherPostretirementBenefitExpense	419000000	USD
CY2015	us-gaap	Pension And Other Postretirement Benefit Expense PensionAndOtherPostretirementBenefitExpense	433000000	USD
CY2014Q2	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	662000000	USD
CY2015Q2	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	1535000000	USD
CY2015Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.20
CY2015Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	128000000	shares
CY2014Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	697000000	USD
CY2015Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1454000000	USD
CY2014Q2	us-gaap	Prepaid Taxes PrepaidTaxes	320000000	USD
CY2015Q2	us-gaap	Prepaid Taxes PrepaidTaxes	427000000	USD
CY2013	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	2980000000	USD
CY2014	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	1994000000	USD
CY2015	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	19942000000	USD
CY2013	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	267000000	USD
CY2014	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	1307000000	USD
CY2015	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	649000000	USD
CY2013	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-22000000	USD
CY2014	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	14000000	USD
CY2015Q1	us-gaap	Sales Revenue Net SalesRevenueNet	4318000000	USD
CY2014Q4	us-gaap	Sales Revenue Net SalesRevenueNet	4366000000	USD
CY2015Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8863000000	USD
CY2013Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2490000000	USD
CY2014Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2392000000	USD
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4699000000	USD
CY2013	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	51000000	USD
CY2015	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-31000000	USD
CY2013	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	-720000000	USD
CY2014	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	127000000	USD
CY2015	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	-1000000	USD
CY2013	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	10511000000	USD
CY2014	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	8111000000	USD
CY2015	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	5890000000	USD
CY2013	us-gaap	Proceeds From Short Term Debt Maturing In More Than Three Months ProceedsFromShortTermDebtMaturingInMoreThanThreeMonths	2628000000	USD
CY2014	us-gaap	Proceeds From Short Term Debt Maturing In More Than Three Months ProceedsFromShortTermDebtMaturingInMoreThanThreeMonths	1176000000	USD
CY2015	us-gaap	Proceeds From Short Term Debt Maturing In More Than Three Months ProceedsFromShortTermDebtMaturingInMoreThanThreeMonths	150000000	USD
CY2014Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6439000000	USD
CY2014	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	43000000	USD
CY2015	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	35000000	USD
CY2014	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax	15000000	USD
CY2015	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax	205000000	USD
CY2014	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	8000000	USD
CY2015	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	128000000	USD
CY2013	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	2214000000	USD
CY2014	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	565000000	USD
CY2015	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1268000000	USD
CY2013	us-gaap	Repayments Of Short Term Debt Maturing In More Than Three Months RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths	2700000000	USD
CY2014	us-gaap	Repayments Of Short Term Debt Maturing In More Than Three Months RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths	1301000000	USD
CY2015	us-gaap	Repayments Of Short Term Debt Maturing In More Than Three Months RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths	150000000	USD
CY2013	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	1557000000	USD
CY2014	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	1477000000	USD
CY2015	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	1640000000	USD
CY2014Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	19940000000	USD
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	54414000000	USD
CY2013	us-gaap	Sales Revenue Net SalesRevenueNet	16590000000	USD
CY2013Q3	us-gaap	Sales Revenue Net SalesRevenueNet	4083000000	USD
CY2013Q4	us-gaap	Sales Revenue Net SalesRevenueNet	4194000000	USD
CY2014Q1	us-gaap	Sales Revenue Net SalesRevenueNet	4163000000	USD
CY2014Q2	us-gaap	Sales Revenue Net SalesRevenueNet	4566000000	USD
CY2014	us-gaap	Sales Revenue Net SalesRevenueNet	17005000000	USD
CY2014Q3	us-gaap	Sales Revenue Net SalesRevenueNet	4273000000	USD
CY2015Q2	us-gaap	Sales Revenue Net SalesRevenueNet	7304000000	USD
CY2015	us-gaap	Sales Revenue Net SalesRevenueNet	20261000000	USD
CY2013	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5698000000	USD
CY2014	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5847000000	USD
CY2015	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6904000000	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	152000000	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	145000000	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	439000000	USD
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0264
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0202
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0166
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.2622
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.2520
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.2129
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0094
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0188
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0099
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.42
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	12.00
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	25.39
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y6M
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y4M24D
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y2M27D
CY2013	us-gaap	Shipping Handling And Transportation Costs ShippingHandlingAndTransportationCosts	182000000	USD
CY2014	us-gaap	Shipping Handling And Transportation Costs ShippingHandlingAndTransportationCosts	194000000	USD
CY2015	us-gaap	Shipping Handling And Transportation Costs ShippingHandlingAndTransportationCosts	284000000	USD
CY2014Q2	us-gaap	Short Term Investments ShortTermInvestments	12838000000	USD
CY2015Q2	us-gaap	Short Term Investments ShortTermInvestments	14637000000	USD
CY2013Q2	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	35000000	USD
CY2014Q2	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	32000000	USD
CY2015Q2	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	135000000	USD
CY2015	us-gaap	Standard Product Warranty Accrual Additions From Business Acquisition StandardProductWarrantyAccrualAdditionsFromBusinessAcquisition	23000000	USD
CY2014	us-gaap	Standard Product Warranty Accrual Payments StandardProductWarrantyAccrualPayments	28000000	USD
CY2015	us-gaap	Standard Product Warranty Accrual Payments StandardProductWarrantyAccrualPayments	24000000	USD
CY2015	us-gaap	Standard Product Warranty Accrual Preexisting Increase Decrease StandardProductWarrantyAccrualPreexistingIncreaseDecrease	74000000	USD
CY2014	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	25000000	USD
CY2015	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	30000000	USD
CY2015	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1872	shares
CY2015	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	33787000000	USD
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	75000	USD
CY2015Q2	us-gaap	Stock Repurchase Program Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased	80000000	shares
CY2013	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	1247000000	USD
CY2014	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	2553000000	USD
CY2015	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	1920000000	USD
CY2014	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	47800000	shares
CY2015	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	29800000	shares
CY2012Q2	us-gaap	Stockholders Equity StockholdersEquity	17113000000	USD
CY2013Q2	us-gaap	Stockholders Equity StockholdersEquity	18671000000	USD
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	19443000000	USD
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	53230000000	USD
CY2015	us-gaap	Stockholders Equity Other StockholdersEquityOther	0	USD
CY2015	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions	349000000	USD
CY2015Q2	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	183000000	USD
CY2013Q2	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	18123000000	USD
CY2014Q2	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	20529000000	USD
CY2015Q2	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	27837000000	USD
CY2012Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	917000000	USD
CY2013Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1068000000	USD
CY2014Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1172000000	USD
CY2015Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2860000000	USD
CY2013	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	21000000	USD
CY2014	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	58000000	USD
CY2015	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	40000000	USD
CY2013	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	6000000	USD
CY2014	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	66000000	USD
CY2015	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	33000000	USD
CY2013Q2	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	88000000	USD
CY2014Q2	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	141000000	USD
CY2015Q2	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	656000000	USD
CY2013	us-gaap	Unrecognized Tax Benefits Increases Resulting From Acquisition UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition	0	USD
CY2014	us-gaap	Unrecognized Tax Benefits Increases Resulting From Acquisition UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition	0	USD
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Acquisition UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition	1199000000	USD
CY2013	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	169000000	USD
CY2014	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	166000000	USD
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	231000000	USD
CY2013	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	12000000	USD
CY2014	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	64000000	USD
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	331000000	USD
CY2013	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	3000000	USD
CY2014	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	2000000	USD
CY2015	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2013Q2	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	1028000000	USD
CY2014Q2	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	1104000000	USD
CY2015Q2	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	2233000000	USD
CY2013	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1027500000	shares
CY2014	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1013600000	shares
CY2015	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1109000000	shares
CY2013	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1019300000	shares
CY2014	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1002100000	shares
CY2015	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1095500000	shares
CY2015	us-gaap	Fiscal Period FiscalPeriod	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fiscal Year-End</font><font style="font-family:inherit;font-size:10pt;"> The Company utilizes a 52/53-week fiscal year, ending the last Friday in April. The Company’s fiscal years </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;"> ended on </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">April 24, 2015</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">April 25, 2014</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">April 26, 2013</font><font style="font-family:inherit;font-size:10pt;">, respectively, all of which were 52-week years. Fiscal year 2016 is a 53-week year, with the extra week occurring during the first quarter. </font></div></div>
CY2015	us-gaap	Guarantees Indemnifications And Warranties Policies GuaranteesIndemnificationsAndWarrantiesPolicies	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Tax Guarantees </font><font style="font-family:inherit;font-size:10pt;">As a result of the recent acquisition of Covidien, the Company has guarantee commitments and indemnifications with Tyco International plc (Tyco International) and TE Connectivity Ltd. (TE Connectivity) which relate to certain contingent tax liabilities as part of a tax sharing agreement. These commitments and indemnifications were recorded at their respective fair values as of the Acquisition Date. Each reporting period, the Company evaluates the potential loss that it believes is probable. This guarantee currently has not been amortized into income because there has been no predictable pattern of performance. As a result, the liability generally will be reduced upon the Company’s release from its obligations or as payments are made. </font></div></div>
CY2015	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contingencies</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company and its affiliates are involved in a number of legal actions involving product liability, intellectual property disputes, shareholder related matters, environmental proceedings, income tax disputes, and other matters. The outcomes of these legal actions are not within the Company’s complete control and may not be known for prolonged periods of time. In some actions, the claimants seek damages, as well as other relief (including injunctions barring the sale of products that are the subject of the lawsuit), that could require significant expenditures or result in lost revenues. When determining the estimated loss or range of loss, significant judgment is required to estimate the amount and timing of a loss to be recorded. Estimates of probable losses resulting from litigation and governmental proceedings involving the Company are inherently difficult to predict, particularly when the matters are in early procedural stages, with incomplete scientific facts or legal discovery; involve unsubstantiated or indeterminate claims for damages; potentially involve penalties, fines or punitive damages; or could result in a change in business practice. In addition to the litigation contingencies referenced below, the Company also has certain guarantee obligations that may potentially result in future costs. While it is not possible to predict the outcome for most of the matters discussed below, the Company believes it is possible that costs associated with them could have a material adverse impact on the Company’s consolidated earnings, financial position, or cash flows. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Product Liability Matters</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Sprint Fidelis</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2007, a putative class action was filed in the Ontario Superior Court of Justice in Canada seeking damages for personal injuries allegedly related to Medtronic, Inc.’s Sprint Fidelis family of defibrillation leads. On October 20, 2009, the court certified a class proceeding but denied class certification on plaintiffs’ claim for punitive damages. Pretrial proceedings are underway. The Company has not recorded an expense related to damages in connection with this matter because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company cannot reasonably estimate the range of loss, if any, that may result from this matter.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">INFUSE Litigation</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of June 1, 2015, plaintiffs had filed approximately </font><font style="font-family:inherit;font-size:10pt;">800</font><font style="font-family:inherit;font-size:10pt;"> lawsuits against Medtronic in the U.S. state and federal courts, reflecting approximately </font><font style="font-family:inherit;font-size:10pt;">1,500</font><font style="font-family:inherit;font-size:10pt;"> individual personal injury claims from the INFUSE bone graft product. Certain law firms have advised Medtronic that they represent a large number of similar claimants against Medtronic. The Company estimates those law firms represent approximately </font><font style="font-family:inherit;font-size:10pt;">4,600</font><font style="font-family:inherit;font-size:10pt;"> unfiled claimants. Medtronic recorded expenses of </font><font style="font-family:inherit;font-size:10pt;">$37 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$140 million</font><font style="font-family:inherit;font-size:10pt;"> in fiscal years 2015 and 2014, respectively, related to probable and reasonably estimated damages and expenses in connection with these matters. See "Accrued Certain Litigation Charges" within Note 1 for additional discussion.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Other INFUSE Litigation</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 5, 2014, Humana, Inc. filed a lawsuit for unspecified monetary damages in the U.S. District Court for the Western District of Tennessee, alleging that Medtronic, Inc. violated federal racketeering (RICO) law and various state laws, by conspiring with physicians to promote unapproved uses of INFUSE. The Company has not recorded an expense related to damages in connection with this matter because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company cannot reasonably estimate the range of loss, if any, that may result from this matter.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Pelvic Mesh Litigation</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Covidien currently is involved in litigation in various state and federal courts against manufacturers of pelvic mesh products alleging personal injuries resulting from the implantation of those products. Two subsidiaries of Covidien supplied pelvic mesh products to one of the manufacturers named in the litigation and Covidien is indemnifying that manufacturer on certain claims. In addition, the Company believes that this manufacturer has an obligation to indemnify Covidien with respect to the promotion of the pelvic mesh products. The litigation includes a federal multi-district litigation in the United States District Court for the Northern District of West Virginia and cases in various state courts and jurisdictions outside the United States. Generally, complaints allege design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. As of June 1, 2015, approximately </font><font style="font-family:inherit;font-size:10pt;">11,300</font><font style="font-family:inherit;font-size:10pt;"> pending cases or claims were filed or estimated to be filed involving products manufactured by Covidien’s subsidiaries. See "Accrued Certain Litigation Charges" within Note 1 for additional discussion.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Patent Litigation</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Ethicon</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 28, 2013, the federal court ruled in favor of Covidien in a patent infringement suit against Ethicon Endo-Surgery, Inc. (Ethicon), a Johnson & Johnson company, relating to Ethicon’s Harmonic</font><font style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> line of ultrasonic surgical products. The federal court awarded Covidien </font><font style="font-family:inherit;font-size:10pt;">$177 million</font><font style="font-family:inherit;font-size:10pt;"> in damages upon ruling that several of Covidien’s patents were valid, enforceable and infringed by Ethicon. Ethicon appealed the decision. On December 4, 2014, the U.S. Court of Appeals for the Federal Circuit reversed the </font><font style="font-family:inherit;font-size:10pt;">$177 million</font><font style="font-family:inherit;font-size:10pt;"> judgment against Ethicon and ruled that the infringed patent claims were invalid. On June 24, 2014, Covidien filed a lawsuit in the U.S. District Court for the District of Connecticut against Ethicon alleging that Ethicon’s ultrasonic surgical product, the Harmonic ACE</font><font style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">®</sup></font><font style="font-family:inherit;font-size:10pt;">+7, infringes three of the Company’s patents. Covidien asked the court to enjoin Ethicon from continuing to make and sell the Harmonic ACE</font><font style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">®</sup></font><font style="font-family:inherit;font-size:10pt;">+7 device and to grant damages for the patent infringement. On October 17, 2014, the district court granted a preliminary injunction against Ethicon, which prevents Ethicon from making and selling the Harmonic ACE</font><font style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">®</sup></font><font style="font-family:inherit;font-size:10pt;">+7 device. Ethicon obtained a temporary stay and appealed this preliminary injunction ruling. On March 25, 2015, the U.S. Court of Appeals for the Federal Circuit reversed the preliminary injunction entered against the Harmonic ACE</font><font style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">®</sup></font><font style="font-family:inherit;font-size:10pt;">+7 and remanded for further proceedings. On May 8, 2015, pursuant to a stipulation of the parties, the U.S. District Court for the District of Connecticut dismissed that case involving the Harmonic ACE</font><font style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">®</sup></font><font style="font-family:inherit;font-size:10pt;">+7. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Ethicon Endo-Surgery, Inc., et al. v. Covidien, Inc., et al</font><font style="font-family:inherit;font-size:10pt;">. is a patent infringement action filed on December 14, 2011 in the United States District Court for the Southern District of Ohio, Western Division. The complaint alleges that Covidien’s Sonicision product infringes several of Ethicon’s design and utility patents. Ethicon is seeking monetary damages and injunctive relief. On January 22, 2014, the district court entered summary judgment in Covidien’s favor, ruling that Covidien does not infringe any of the seven Ethicon patents in dispute and declaring five of Ethicon’s patents invalid. Ethicon has appealed the district court’s decision. Oral argument before the U.S. Court of Appeals for the Federal Circuit was held March 6, 2015. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has not recorded an expense related to damages in connection with the patent litigation matters because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company cannot reasonably estimate the range of loss, if any, that may result from these matters.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Shareholder Related Matters</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">INFUSE</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 12, 2012, Charlotte Kokocinski filed a shareholder derivative action against both Medtronic, Inc. and certain of its current and former officers and members of its Board of Directors in the U.S. District Court for the District of Minnesota, setting forth certain allegations, including a claim that defendants violated various purported duties in connection with the INFUSE bone graft product and otherwise. On March 25, 2013, the Court dismissed the case without prejudice. On March 30, 2015, the Court granted defendants’ motion to dismiss the Amended Complaint, dismissing the case with prejudice. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2012, Daniel Himmel and the Saratoga Advantage Trust commenced two other separate shareholder derivative actions in Hennepin County, Minnesota, District Court against the same defendants, making allegations similar to those in the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Kokocinski</font><font style="font-family:inherit;font-size:10pt;"> case. On July 1, 2014, Road Carriers Local 707 Welfare & Pension Funds filed a shareholder derivative action in Hennepin County, Minnesota, District Court against the same defendants making allegations similar to those in the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Kokocinski, Himmel,</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Saratoga Advantage Trust</font><font style="font-family:inherit;font-size:10pt;"> cases. On July 24, 2014, Anne Shirley Cutler filed a shareholder derivative action in Hennepin County, Minnesota, District Court against certain of the same defendants making allegations similar to those in the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Kokocinski, Himmel,</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Saratoga Advantage Trust</font><font style="font-family:inherit;font-size:10pt;"> cases as well as allegations that defendants violated purported duties in connection with the Synchromed pain pump system. On May 26, 2015, the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Himmel</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Saratoga Advantage Trust</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Road Carriers Local 707</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cutler</font><font style="font-family:inherit;font-size:10pt;"> plaintiffs filed Voluntary Stipulations of Dismissal with Prejudice or statements of non-opposition to dismissal of all INFUSE-related claims and allegations. On June 4, 2015, the Court preliminarily approved the INFUSE-related dismissals with prejudice subject to shareholder notice and an opportunity to intervene. On June 9, 2015, the Company provided notice of the Court's order in a Form 8-K filing.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 26, 2014, Richard Hockstein filed an INFUSE-related shareholder derivative action against both Medtronic, Inc. and certain of its current and former officers and members of its Board of Directors in the United States District Court for the District of Minnesota making allegations similar to those in the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Kokocinski </font><font style="font-family:inherit;font-size:10pt;">case. West Virginia Pipe Trades and Phil Pace, on June 27, 2013 and July 3, 2013, respectively, filed putative class action complaints against Medtronic, Inc. and certain of its officers in the U.S. District Court for the District of Minnesota, alleging that the defendants made false and misleading public statements regarding the INFUSE Bone Graft product during the period of December 8, 2010 through August 3, 2011. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Shareholder Related Matters Resulting from the Covidien Acquisition</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 2, 2014, Lewis Merenstein filed a putative shareholder class action in Hennepin County, Minnesota, District Court seeking to enjoin the then-potential acquisition of Covidien. The lawsuit named Medtronic, Inc., Covidien, and each member of the Medtronic, Inc. board at the time as defendants, and alleged that the directors breached their fiduciary duties to shareholders with regard to the then-potential acquisition. On August 21, 2014, Kenneth Steiner filed a putative shareholder class action in Hennepin County, Minnesota, District Court, also seeking an injunction to prevent the potential Covidien acquisition. In September of 2014, the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Merenstei</font><font style="font-family:inherit;font-size:10pt;">n and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Steiner</font><font style="font-family:inherit;font-size:10pt;"> matters were consolidated and in December of 2014, the plaintiffs filed a preliminary injunction motion seeking to enjoin the Covidien transaction. On December 30, 2014, a hearing was held on plaintiffs’ motion for preliminary injunction and on defendants’ motion to dismiss. On January 2, 2015, the Court denied the plaintiffs’ motion for preliminary injunction and on January 5, 2015 issued its opinion. On March 20, 2015, the Court issued its order and opinion granting Medtronic’s motion to dismiss the case. In May of 2015, the plaintiffs filed an appeal with the Minnesota State Court of Appeals.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the then-potential acquisition of Covidien, on September 19, 2014, William A. Houston filed a putative shareholder class action in the United States District Court for the District of Minnesota and on October 3, 2014, Marilyn Clark filed a complaint in the United States District Court for the District of Minnesota that is nearly identical to the Houston complaint. These actions named as defendants certain members of Medtronic, Inc.’s board of directors at the time and certain of Medtronic, Inc.’s officers, and also named Medtronic, Inc. as a nominal defendant. The </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Houston</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Clark</font><font style="font-family:inherit;font-size:10pt;"> complaints asserted various causes of action under Minnesota law, including that the individual defendants allegedly breached fiduciary duties in providing for excise tax reimbursements to certain individuals who were and/or are directors and executive officers of Medtronic, Inc. in connection with the then-potential acquisition of Covidien. In October of 2014, the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Houston</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Clark</font><font style="font-family:inherit;font-size:10pt;"> matters were consolidated and the plaintiffs filed a preliminary injunction motion seeking to enjoin the Company from the payment of the excise tax reimbursements. On December 16, 2014, the Court heard the preliminary injunction motion and on December 22, 2014, the Court denied the preliminary injunction motion. On January 6, 2015, the Company consented to plaintiffs’ request to voluntarily dismiss the matter without prejudice. On January 7, 2015, the Court entered its order of dismissal, bringing these matters to a conclusion.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Putative shareholder class action complaints have been filed in the United States District Court for the District of Massachusetts by purported shareholders of Covidien under the captions </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Taxman v. Covidien plc, et al</font><font style="font-family:inherit;font-size:10pt;">., 14-cv-12949, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Lipovich v. Covidien plc, et al</font><font style="font-family:inherit;font-size:10pt;">., 14-cv-13308 and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Rosenfeld Family Foundation v. Covidien plc, et al</font><font style="font-family:inherit;font-size:10pt;">., 14-cv-13490. On October 20, 2014, the plaintiff in the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Rosenfeld</font><font style="font-family:inherit;font-size:10pt;"> action and another purported shareholder of Covidien filed a motion seeking to consolidate the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Taxman, Lipovich</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Rosenfeld</font><font style="font-family:inherit;font-size:10pt;"> actions, and on November 14, 2014, the United States District Court for the District of Massachusetts granted that motion consolidating the actions (the Consolidated Action). On December 23, 2014, the defendants reached an agreement in principle with plaintiffs in the Consolidated Action, and that agreement is reflected in a memorandum of understanding. In connection with the settlement contemplated by the memorandum of understanding, Covidien agreed to make certain additional disclosures related to the Transactions, which are contained in Covidien’s Report on Form 8-K filed on December 23, 2014. The memorandum of understanding contemplates that the parties will enter into a stipulation of settlement.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A stipulation of settlement was filed with the court on May 15, 2015, and a hearing will be scheduled at which the United States District Court for the District of Massachusetts will consider the fairness, reasonableness, and adequacy of the settlement, including attorneys' fees and expenses that will be paid to plaintiffs' counsel. If the settlement is finally approved by the court, it will resolve and release all claims in all actions that were or could have been brought by Covidien shareholders challenging any aspect of the Transactions. There can be no assurance that United States District Court for the District of Massachusetts will approve the settlement. In such event, the proposed settlement as contemplated by the memorandum of understanding may be terminated.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has not recorded an expense related to damages in connection with the shareholder related matters because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company cannot reasonably estimate the range of loss, if any, that may result from these matters.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Environmental Proceedings</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Covidien is involved in various stages of investigation and cleanup related to environmental remediation matters at a number of sites. These projects relate to a variety of activities, including removal of solvents, metals and other hazardous substances from soil and groundwater. The ultimate cost of site cleanup and timing of future cash flows is difficult to predict given uncertainties regarding the extent of the required cleanup, the interpretation of applicable laws and regulations, and alternative cleanup methods. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Covidien is a successor to a company which owned and operated a chemical manufacturing facility in Orrington, Maine from 1967 until 1982, and is responsible for the costs of completing an environmental site investigation as required by the Maine Department of Environmental Protection (MDEP). MDEP served a compliance order on Mallinckrodt LLC and United States Surgical Corporation in December 2008. The compliance order included a directive to remove a significant volume of soils at the site. On December 19, 2008, Covidien filed an appeal with the Maine Board of Environmental Protection (Maine Board) to challenge the terms of the compliance order. A hearing before the Maine Board began on January 25, 2010 and concluded on February 4, 2010. On August 19, 2010, the Maine Board modified the MDEP order and issued a final order requiring removal of two landfills, capping of the remaining three landfills, installation of a groundwater extraction system and long-term monitoring of the site and the three remaining landfills. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 3, 2014, the Maine Supreme Judicial Court affirmed the Maine Board’s compliance order. Covidien has proceeded with implementation of the investigation and remediation at the site in accordance with the MDEP order as modified by the Maine Board order. See "Accrued Certain Litigation Charges" within Note 1 for additional discussion.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Covidien has also been involved in a lawsuit filed in the U.S. District Court for the District of Maine by the Natural Resources Defense Council and the Maine People’s Alliance. Plaintiffs sought an injunction requiring Covidien to conduct extensive studies of mercury contamination of the Penobscot River and Bay and options for remediating such contamination, and to perform appropriate remedial activities, if necessary. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 29, 2002, following a March 2002 trial, the District Court entered an opinion and order which held that conditions in the Penobscot River and Bay may pose an imminent and substantial endangerment and that Covidien was liable for the cost of performing a study of the river and bay. The District Court subsequently appointed an independent study panel to oversee the study and ordered Covidien to pay costs associated with the study. A report issued by the study panel contains recommendations for a variety of potential remedial options which could be implemented individually or in a variety of combinations, and includes preliminary cost estimates for the potential remedial options, which the report describes as “very rough estimates of cost,” ranging from </font><font style="font-family:inherit;font-size:10pt;">$25 million</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$235 million</font><font style="font-family:inherit;font-size:10pt;">. The report indicates that these costs are subject to uncertainties, and that before any remedial option is implemented, further engineering studies and engineering design work are necessary to determine the feasibility of the proposed remedial options. In June of 2014, a trial was held to determine if remediation was necessary and feasible, and, at a post-trial hearing on June 18, 2015, the Court indicated that further engineering study and engineering design work is appropriate to determine the nature and extent of remediation in the Penobscot River and Bay. See "Accrued Certain Litigation Charges" within Note 1 for additional discussion.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Matters</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">One of Covidien’s subsidiaries, ev3 Inc., (ev3) acquired Appriva Medical, Inc. in 2002. The acquisition agreement relating to ev3’s acquisition of Appriva Medical contained four contingent milestone payments totaling </font><font style="font-family:inherit;font-size:10pt;">$175 million</font><font style="font-family:inherit;font-size:10pt;">. ev3 determined that the milestones were not achieved by the applicable dates and that none of the milestones were payable. On April 7, 2009, Michael Lesh and Erik Van Der Burg, acting jointly as the Shareholder Representatives for the former shareholders of Appriva Medical, filed a motion to amend their previously dismissed complaints in Superior Court of the State of Delaware. The plaintiffs asserted several claims, including breach of contract, fraudulent inducement and violation of California securities law. On May 1, 2013, the jury returned a verdict finding that ev3 breached the merger agreement and awarded </font><font style="font-family:inherit;font-size:10pt;">$175 million</font><font style="font-family:inherit;font-size:10pt;"> in damages plus interest to the plaintiffs. On September 30, 2014, the Delaware Supreme Court reversed the jury’s verdict and remanded the case for a new trial. See "Accrued Certain Litigation Charges" within Note 1 for additional discussion.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medtronic has received subpoenas or document requests from the Attorneys General in Massachusetts, California, Oregon, Illinois, and Washington seeking information regarding sales, marketing, clinical, and other information relating to the INFUSE bone graft product. The Company is fully cooperating with these requests.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 3, 2013, Medtronic, Inc. received a subpoena for records from the U.S. Attorney’s Office for the District of Minnesota requesting information relating to Medtronic, Inc’s compliance with the Trade Agreements Act. In April 2015, the Company settled this matter with no admission of liability and recorded a certain litigation charge of </font><font style="font-family:inherit;font-size:10pt;">$4 million</font><font style="font-family:inherit;font-size:10pt;"> in fiscal year 2015.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 2, 2011, the U.S. Attorney’s Office for the District of Massachusetts issued a subpoena to ev3, a subsidiary of the Company, requesting production of documents relating to sales and marketing and other issues in connection with several neurovascular products. The matters under investigation relate to activities prior to Covidien's acquisition of ev3 in 2010. ev3 complied as required with the subpoena and cooperated with the investigation. The Company is fully cooperating with these requests.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 2, 2014, the U.S. Department of Health and Human Services, Office of Inspector General and the U.S. Attorney’s Office for the Northern District of California, issued a subpoena requesting production of documents relating to sales and marketing practices associated with certain of ev3’s peripheral vascular products. The Company is fully cooperating with these requests.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Except as noted above, the Company has not recorded an expense related to damages in connection with the issued subpoenas because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company cannot reasonably estimate the range of loss, if any, that may result from these matters.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2009, the U.S. Internal Revenue Service (IRS) issued its audit report on Medtronic, Inc. for fiscal years 2005 and 2006. Medtronic, Inc. reached agreement with the IRS on some, but not all matters related to these fiscal years. On December 23, 2010, the IRS issued a statutory notice of deficiency with respect to the remaining issues. Medtronic, Inc. filed a Petition with the U.S. Tax Court on March 21, 2011 objecting to the deficiency. During October and November 2012, Medtronic, Inc. reached resolution with the IRS on various matters, including the deductibility of a settlement payment. Medtronic, Inc. and the IRS agreed to hold one issue, the calculation of amounts eligible for the one-time repatriation holiday, because such specific issue was being addressed by other taxpayers in litigation with the IRS. The remaining unresolved issue for fiscal years 2005 and 2006 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, which is one of the Company's key manufacturing sites. The Tax Court proceeding with respect to this issue began on February 3, 2015 and ended on March 12, 2015. The Company expects a ruling from the Tax Court sometime during fiscal year 2017.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2011, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2007 and 2008. Medtronic, Inc. reached agreement with the IRS on some but not all matters related to these fiscal years. The significant issues that remain unresolved relate to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico and proposed adjustments associated with the tax effects of the Company's acquisition of Kyphon Inc. (Kyphon). During the fourth quarter of fiscal year 2015, a tentative settlement was reached with the IRS for the Kyphon acquisition matters. As a result, the Company recorded a </font><font style="font-family:inherit;font-size:10pt;">$329 million</font><font style="font-family:inherit;font-size:10pt;"> certain tax adjustment, including interest, during fiscal year 2015.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2014, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2009, 2010, and 2011. Medtronic, Inc. reached agreement with the IRS on some but not all matters related to these fiscal years. The significant issues that remain unresolved relate to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, and proposed adjustments associated with the tax effects of its acquisition structures for Ardian, CoreValve, Inc., and Ablation Frontiers, Inc. The Company disagrees with the IRS and will attempt to resolve these matters at the IRS Appellate level, however, it will proceed through litigation, if necessary. The IRS continues to audit Medtronic, Inc.'s U.S. federal income tax returns for the fiscal years 2012 through 2014.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Covidien and the IRS have concluded and reached agreement on its audit of Covidien’s U.S. federal income tax returns for the 2008 and 2009 tax years. The IRS continues to audit Covidien’s U.S. federal income tax returns for the years 2010 through 2012. Open periods for examination also include certain periods during which Covidien was a subsidiary of Tyco International. The resolution of these matters is subject to the conditions set forth in the Tyco tax sharing agreement. Tyco International has the right to administer, control and settle all U.S. income tax audits for periods prior to the 2007 separation.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The IRS has concluded its field examination of certain of Tyco International’s U.S. federal income tax returns for the years 1997 through 2000 and proposed tax adjustments, several of which also affect Covidien’s income tax returns for certain years after 2000. Tyco International has appealed certain of the tax adjustments proposed by the IRS and has resolved all but one of the matters associated with the proposed tax adjustments. With respect to the outstanding issue that remains in dispute, on June 20, 2013, Tyco International advised Covidien that it had received Notices of Deficiency from the IRS asserting that several of Tyco International’s former U.S. subsidiaries owe additional taxes of </font><font style="font-family:inherit;font-size:10pt;">$914 million</font><font style="font-family:inherit;font-size:10pt;"> plus penalties of </font><font style="font-family:inherit;font-size:10pt;">$154 million</font><font style="font-family:inherit;font-size:10pt;"> based on audits of the 1997 through 2000 tax years of Tyco International and its subsidiaries as they existed at that time. These amounts exclude interest and do not reflect the impact on subsequent periods if the IRS position is ultimately proved correct. The IRS has asserted in the Notices of Deficiency that substantially all of Tyco International’s intercompany debt originating during the years 1997 through 2000 should not be treated as debt for U.S. federal income tax purposes, and has disallowed interest deductions related to the intercompany debt and certain tax attribute adjustments recognized on Tyco International’s U.S. income tax returns totaling approximately </font><font style="font-family:inherit;font-size:10pt;">$3.0 billion</font><font style="font-family:inherit;font-size:10pt;">. The Company disagrees with the IRS’s proposed adjustments. On July 22, 2013, Tyco International filed a petition with the U.S. Tax Court contesting the IRS assessment. The Company believes there are meritorious defenses for the tax filings in question, that the IRS positions with regard to these matters are inconsistent with the applicable tax laws and existing Treasury regulations, and that the previously reported taxes for the years in question are appropriate.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No payments with respect to these matters or any additional matters that may be raised by the U.S. Tax Court would be required until the dispute is definitively resolved, which could take several years. The timing and outcome of such litigation is highly uncertain and could have a material adverse effect on the Company’s consolidated financial statements. In particular, if the IRS is successful in asserting its claim, it would likely assert that approximately </font><font style="font-family:inherit;font-size:10pt;">$6.6 billion</font><font style="font-family:inherit;font-size:10pt;"> of interest deductions with respect to Tyco International’s intercompany debt in subsequent time periods should also be disallowed. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Covidien’s income tax returns for the years 2001 through 2003 remain subject to adjustment by the IRS upon ultimate resolution of the disputed issue involving certain intercompany loans that originated during 1997 through 2000. Covidien and the IRS have effectively settled its audits of tax matters for the years 2004 through 2007.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See Note 12 for additional discussion of income taxes.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Guarantees</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the recent acquisition of Covidien, the Company has guarantee commitments and indemnifications with Tyco International, TE Connectivity, and Mallinckrodt plc (Mallinckrodt) which relate to certain contingent tax liabilities. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 29, 2007, Covidien entered into a tax sharing agreement, under which Covidien shares responsibility for certain of its, Tyco International’s and TE Connectivity’s income tax liabilities for periods prior to Covidien’s 2007 separation from Tyco International (2007 separation). Covidien, Tyco International and TE Connectivity share </font><font style="font-family:inherit;font-size:10pt;">42%</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">27%</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">31%</font><font style="font-family:inherit;font-size:10pt;">, respectively, of U.S. income tax liabilities that arise from adjustments made by tax authorities to Covidien's, Tyco International’s and TE Connectivity’s U.S. income tax returns, certain income tax liabilities arising from adjustments made by tax authorities to intercompany transactions or similar adjustments, and certain taxes attributable to internal transactions undertaken in anticipation of the 2007 separation. If Tyco International and TE Connectivity default on their obligations to Covidien under the Tyco tax sharing agreement, the Company would be liable for the entire amount of these liabilities. All costs and expenses associated with the management of these tax liabilities are being shared equally among the parties.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the 2007 separation, all tax liabilities associated with Covidien business became Covidien’s tax liabilities. Following Covidien’s spin-off of its Pharmaceuticals business to Covidien shareholders through a distribution of all the outstanding ordinary shares of Mallinkrodt (2013 separation), Mallinckrodt became the primary obligor to the taxing authorities for the tax liabilities attributable to its subsidiaries, a significant portion of which relate to periods prior to the 2007 separation. However, Covidien remains the sole party subject to the tax sharing agreement with Tyco International and TE Connectivity. Accordingly, Mallinckrodt does not share in Covidien’s liability to Tyco International and TE Connectivity, nor in the receivable that Covidien has from Tyco International and TE Connectivity.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If any party to the Tyco tax sharing agreement were to default in its obligation to another party to pay its share of the distribution taxes that arise as a result of no party’s fault, each non-defaulting party would be required to pay, equally with any other non-defaulting party, the amounts in default. In addition, if another party to the Tyco tax sharing agreement that is responsible for all or a portion of an income tax liability were to default in its payment of such liability to a taxing authority, the Company could be legally liable under applicable tax law for such liabilities and be required to make additional tax payments. Accordingly, under certain circumstances, the Company may be obligated to pay amounts in excess of the Company’s agreed upon share of Covidien's, Tyco International’s and TE Connectivity’s tax liabilities.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has used available information to develop its best estimates for certain assets and liabilities related to periods prior to the 2007 separation, including amounts subject to or impacted by the provisions of the Tyco tax sharing agreement. The actual amounts that the Company may be required to ultimately accrue or pay under the Tyco tax sharing agreement, however, could vary depending upon the outcome of the unresolved tax matters. Final determination of the balances will be made in subsequent periods, primarily related to certain pre-2007 separation tax liabilities and tax years open for examination. These balances will also be impacted by the filing of final or amended income tax returns in certain jurisdictions where those returns include a combination of Tyco International, Covidien and/or TE Connectivity legal entities for periods prior to the 2007 separation. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In conjunction with the 2013 separation, Mallinckrodt assumed the tax liabilities that are attributable to its subsidiaries, and Covidien indemnified Mallinckrodt to the extent that such tax liabilities arising from periods prior to 2013 exceed </font><font style="font-family:inherit;font-size:10pt;">$200 million</font><font style="font-family:inherit;font-size:10pt;">, net of certain tax benefits realized. In addition, in connection with the 2013 separation, Covidien entered into certain other guarantee commitments and indemnifications with Mallinckrodt.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> "</font><font style="font-family:inherit;font-size:10pt;">Tax Guarantees" within Note 1 for additional discussion.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Except as described above or certain income tax related matters, the Company has not recorded an expense related to losses in connection with these matters because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company cannot reasonably estimate the range of loss, if any, that may result from these matters.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the normal course of business, the Company and/or its affiliates periodically enter into agreements that require one or more of them to indemnify customers or suppliers for specific risks, such as claims for injury or property damage arising out of the Company or its affiliates’ products or the negligence of any of their personnel or claims alleging that any of their products infringe third-party patents or other intellectual property. The Company’s maximum exposure under these indemnification provisions cannot be estimated, and the Company has not accrued any liabilities within the consolidated financial statements. Historically, the Company has not experienced significant losses on these types of indemnifications.</font></div></div>
CY2015	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nature of Operations </font><font style="font-family:inherit;font-size:10pt;">Medtronic plc (Medtronic plc, Medtronic or the Company), the successor registrant to Medtronic, Inc., a Minnesota corporation, was incorporated in Ireland on June 12, 2014 as a private limited company, and was re-registered effective </font><font style="font-family:inherit;font-size:10pt;">January 26, 2015</font><font style="font-family:inherit;font-size:10pt;"> as a public limited company. The Company was established for the purpose of facilitating the acquisition of Covidien plc, a public limited company organized under the laws of Ireland (Covidien), which closed on </font><font style="font-family:inherit;font-size:10pt;">January 26, 2015</font><font style="font-family:inherit;font-size:10pt;"> (Acquisition Date). Upon completion of this transaction, Medtronic replaced Medtronic, Inc., as the ultimate parent company of the Medtronic group. This part of the transaction was accounted for in the consolidated financial statements as a merger between entities under common control; accordingly, the historical consolidated financial statements of Medtronic, Inc. for periods prior to this transaction are considered to be the historical financial statements of the Company.</font></div></div>

Files In Submission

Name	View Source	Status
0001613103-15-000028-index-headers.html	Edgar Link	pending
0001613103-15-000028-index.html	Edgar Link	pending
0001613103-15-000028.txt	Edgar Link	pending
0001613103-15-000028-xbrl.zip	Edgar Link	pending
chart1_2015worldwide.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
mdt-20150424.xml	Edgar Link	completed
mdt-20150424.xsd	Edgar Link	pending
mdt-20150424xex121.htm	Edgar Link	pending
mdt-20150424xex21.htm	Edgar Link	pending
mdt-20150424xex23.htm	Edgar Link	pending
mdt-20150424xex24.htm	Edgar Link	pending
mdt-20150424xex311.htm	Edgar Link	pending
mdt-20150424xex312.htm	Edgar Link	pending
mdt-20150424xex321.htm	Edgar Link	pending
mdt-20150424xex322.htm	Edgar Link	pending
mdt-20150424_cal.xml	Edgar Link	unprocessable
mdt-20150424_def.xml	Edgar Link	unprocessable
mdt-20150424_lab.xml	Edgar Link	unprocessable
mdt-20150424_pre.xml	Edgar Link	unprocessable
mdt-20150425xex1065.htm	Edgar Link	pending
mdt-2015424x10k.htm	Edgar Link	pending
mdt-2015424x10k_charta01a01.jpg	Edgar Link	pending
mdtlogo01a01.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MDT
Medtronic plc Stock $mdt

2015 Q2 Form 10-K Financial Statement

#000161310315000028 Filed on June 23, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDT Medtronic plc Stock $mdt

2015 Q2 Form 10-K Financial Statement

#000161310315000028 Filed on June 23, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDT
Medtronic plc Stock $mdt